What is HC Wainwright’s Forecast for ANIX Q1 Earnings?

Anixa Biosciences, Inc. (NASDAQ:ANIX) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Anixa Biosciences in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of ($0.10) per share for the quarter. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Anixa Biosciences’ current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Anixa Biosciences’ Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.40) EPS.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10).

Several other analysts have also recently issued reports on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday. Maxim Group started coverage on Anixa Biosciences in a report on Friday, March 21st. They issued a “buy” rating and a $10.00 price target for the company.

Anixa Biosciences Price Performance

Anixa Biosciences stock opened at $3.15 on Wednesday. The company has a fifty day simple moving average of $2.95 and a 200-day simple moving average of $3.01. The firm has a market capitalization of $101.42 million, a price-to-earnings ratio of -8.08 and a beta of 0.86. Anixa Biosciences has a 52-week low of $2.07 and a 52-week high of $4.20.

Insider Activity at Anixa Biosciences

In other Anixa Biosciences news, CEO Amit Kumar purchased 43,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was acquired at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the acquisition, the chief executive officer now owns 559,925 shares in the company, valued at $1,248,632.75. This trade represents a 8.32 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the business’s stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average cost of $2.57 per share, with a total value of $25,700.00. Following the completion of the transaction, the director now directly owns 922,334 shares in the company, valued at approximately $2,370,398.38. The trade was a 1.10 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 75,289 shares of company stock valued at $177,021. 25.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Millennium Management LLC purchased a new stake in shares of Anixa Biosciences in the 4th quarter valued at approximately $26,000. Virtu Financial LLC purchased a new stake in Anixa Biosciences in the third quarter valued at approximately $34,000. Renaissance Technologies LLC lifted its stake in Anixa Biosciences by 36.5% during the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after purchasing an additional 3,900 shares in the last quarter. Prosperity Wealth Management Inc. acquired a new position in Anixa Biosciences during the fourth quarter worth $54,000. Finally, Jane Street Group LLC purchased a new position in shares of Anixa Biosciences during the fourth quarter worth $67,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.